ClinicalTrials.Veeva

Menu

Lysophosphatidylglycerol in Asthma Pathogenesis

P

Peking University

Status

Enrolling

Conditions

Asthma

Study type

Observational

Funder types

Other

Identifiers

NCT06327516
M2020023

Details and patient eligibility

About

The study aims to investigate the relationship between the small molecule metabolite lysophosphatidylglycerol and asthma clinical features and explore its involvement in asthma pathogenesis.

Full description

This study screened LPG as a asthma marker by performing metabolomics of the included asthma patients and normal controls, explored the relationship between LPG and clinical features of asthma (including acute exacerbation, asthma control state, asthma treatment steps,lung function, and inflammatory signals including eosinophils, FeNO and total IgE), and further performed in vitro tests to investigate the specific mechanism of LPG's involvement in asthma inflammation through its influence on Treg function.

Enrollment

250 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. clinical diagnosis of asthma.

Exclusion criteria

  1. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor
  2. Combined with acute and chronic respiratory failure
  3. Combined with severe cardiovascular disease
  4. Pregnant woman.

Trial contacts and locations

1

Loading...

Central trial contact

Chun Chang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems